A senior women’s health official at the Food and Drug Administration resigned on Wednesday to protest the agency’s failure to approve over-the-counter sales of a “morning-after” contraceptive despite favorable recommendations from staff scientists. The FDA said Friday it was indefinitely postponing a decision on Barr Pharamceuticals Inc.'s (BRL.N: Quote, Profile, Research) bid to sell the Plan B contraceptive without a prescription.
